Literature DB >> 3025503

Neoexpression of ABH and Lewis blood group antigens in human hepatocellular carcinomas.

Y Okada, T Arima, K Togawa, H Nagashima, K Jinno, S Moriwaki, T Kunitomo, J Thurin, H Koprowski.   

Abstract

Expression of blood group ABH, Lewis, and sialylated-Lea antigens in human hepatocellular carcinomas and the adjacent nontumorous liver tissues was investigated with the use of seven monoclonal antibodies against these carbohydrate determinants. Chromatogram antibody-binding assay and solid-phase enzyme immunoassay of the upper-phase neutral glycolipids revealed the tumor-associated expression of blood group A-active glycolipids incompatible with blood-type status of the patients, a blood group A-active glycolipid with mobility on thin-layer chromatography between the known 6- and 8-sugar blood group A-active glycolipids in human erythrocytes, blood group H-active glycolipids, and blocked synthesis of Lea-active glycolipids with or without concomitant accumulation of Leb-active glycolipids. Immunohistochemical analysis of the fixed tissues with the use of an avidin-biotin-peroxidase complex method revealed blood group antigens in biliary epithelial cells but not in parenchymal liver cells. However, hepatocellular carcinoma cells in some cases expressed H and Leb antigens. Although only type 1 chain H antigen was detected in biliary epithelial cells, both type 1 and type 2 chain H antigens were found in hepatocellular carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3025503     DOI: 10.1093/jnci/78.1.19

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

2.  Hepatocellular expression of a novel glycoprotein with sialylated difucosyl Lex activity in the active inflammatory lesions of chronic liver disease.

Authors:  Y Okada; T Shimoe; M Muguruma; R Usumoto; T Tsuji; K Jinno; S Moriwaki; S Shin; S Hakomori
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis.

Authors:  S Bloom; A Heryet; K Fleming; R W Chapman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

4.  Comparative study on the expression of the blood group antigens Le a, Le b, Le x, Le y and the carbohydrate antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.

Authors:  J Schwenk; J Makovitzky
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Authors:  Qiang Li; Cui-Hua Yu; Jin-Hong Yu; Li Liu; Shuang-Shuang Xie; Wen-Wen Li; Xia Yang; Wen-Bo Fan; Zhong-Tao Gai; Shi-Jun Chen; Naoya Kato
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

6.  ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization.

Authors:  Kittipitch Bannangkoon; Keerati Hongsakul; Pimsiri Sripongpun; Apichat Kaewdech; Naichaya Chamroonkul; Teeravut Tubtawee; Teerha Piratvisuth
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

Review 7.  Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.

Authors:  Magdalena Thurin
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2021-06

8.  ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.

Authors:  Joyce Yongxu Huang; Renwei Wang; Yu-Tang Gao; Jian-Min Yuan
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

9.  The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients.

Authors:  S Yazawa; T Asao; H Izawa; Y Miyamoto; K L Matta
Journal:  Jpn J Cancer Res       Date:  1988-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.